Pharmacological efforts to modulate these ROS–RCD axes are already underway: ferroptosis inducers (such as erastin derivatives and GPX4 inhibitors) are being explored for drug-resistant cancers [329,330], whereas RIPK1-targeting necroptosis inhibitors (e.g., necrostatins, GSK2982772) and NLRP3 inflammasome blockers (such as MCC950) have entered preclinical and early clinical testing for inflammatory and degenerative diseases [331,332,333,334,335]. The gene discussed is NLRP3; the disease is cancer.